• Users Online: 303
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2022  |  Volume : 9  |  Issue : 4  |  Page : 299-303

Evaluation of a novel local drug delivery system containing tetracycline hydrochloride microparticles as an adjunct to mechanotherapy in the management of chronic periodontitis

1 Department of Periodontics, Nair Hospital Dental College, Mumbai, Maharashtra, India
2 Department of Pharmaceutics, Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India

Correspondence Address:
Nikita Dilip Patil
Department of Periodontics, Nair Hospital Dental College, Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdrr.jdrr_50_22

Rights and Permissions

Background: Tetracycline hydrochloride is a primarily used antimicrobial for periodontitis. Due to its limitations when used systemically, local application in the subgingival zone is encouraged. The local concentration of the drug can be maximized further by optimizing its delivery vehicle. Aim and Objectives: The aim was to compare and assess the efficacy of novel drug formulation containing tetracycline microparticles with commercially available tetracycline fibers as local drug delivery agents in patients with chronic periodontitis. Materials and Methods: A total of 10 patients in the age group of 23–53 years with chronic periodontitis were selected. Patients having isolated periodontal pockets with probing pocket depth (PPD) >5 mm were selected. They were randomized into Group A (scaling and root planning [SRP] + tetracycline microparticles) and Group B (SRP + tetracycline fibers). Clinical parameters such as plaque index, gingival index, probing pocket depth (PPD), and clinical attachment level (CAL) were recorded at 0 and 90 days. The data obtained were consolidated and subjected to statistical analysis. Results: Both the groups confirmed statistically significant improvement in all the clinical parameters. Results of the study showed enhanced CAL gain in Group A compared to Group B. Conclusion: The novel drug formulation is equally efficacious to the commercially available formulation, with decreased manufacturing cost and greater drug availability. Nevertheless, more clinical trials are necessary to study the long-term results.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal